Veeva Systems on September 1, 2026 announced Veeva Falcon Safety, an agentic product designed to streamline adverse event intake, case processing, and follow-up for biopharma companies of all sizes. Veeva said the product aims to reduce costs, increase speed, and maintain compliance in pharmacovigilance operations.
Falcon Safety is planned for early adopter availability in November 2026 and is part of Veeva AI, the company’s industry-specific AI solutions for life sciences.
Interoperability Across E2B-Compliant Systems
In addition to working with Veeva’s own safety application, the company said Falcon Safety will provide intake and follow-up management for any E2B-compliant safety system, naming Oracle Argus and ArisGlobal LifeSphere MultiVigilance as examples.
E2B is the data standard for the electronic transmission of individual case safety reports, or ICSRs, which document suspected adverse reactions to medicines. According to the U.S. Food and Drug Administration, E2B(R3) is endorsed by the International Council for Harmonisation and adopted by the FDA for electronic ICSR submissions. FDA began accepting postmarketing ICSRs in the E2B(R3) format on January 16, 2024, and will require all ICSRs submitted through its next-generation electronic gateway to use the standard beginning October 1, 2026.
By committing to operate across E2B-compliant systems, Veeva said Falcon Safety can handle adverse event intake and follow-up for organizations that run safety databases other than its own.
The Agentic Platform Behind the Product
Falcon Safety is the safety offering within Veeva Falcon, the company’s agentic platform of standard AI agents for life sciences. Veeva describes Falcon agents as a workforce that executes complex, multi-step business processes end-to-end, operating natively with Vault applications and data while following best-practice processes and customer business rules. The agents escalate to people only for exceptions, and every action generates a verifiable audit trail, the company said.
Veeva first announced Falcon on May 27, 2026 as an agentic platform and set of standard agents for major drug development processes, working with its clinical, regulatory, and safety applications. The initial announcement identified safety case triage and intake among the initial focus areas, alongside trial master file document intake and health authority correspondence. Falcon MLR, an agent for content compliance checks, is available today, while the first agents for clinical, regulatory, and safety are planned for availability in November 2026, the company said.
Falcon operates at the agent layer of what Veeva calls the MAAP architecture — models, agents, applications — with agents working natively inside Vault applications that serve as systems of record for data and business rules.
Built With Pharmacovigilance Input
Veeva said it developed its safety products with input from practitioners. “We’ve had the privilege of working closely with case processors, pharmacovigilance experts, and safety specialists globally to build Veeva Safety,” said Marius Mortensen, vice president of product, Falcon at Veeva. “With Falcon Safety, we’re excited to build on that partnership to help the industry reinvent safety operations.”
The safety operations layer Falcon Safety automates sits on top of the case management that Veeva Safety already provides. Veeva Safety is a modern individual case safety report management system that handles the intake, processing, and submission of adverse events for clinical and post-marketed products. Sponsors and contract research organizations use it to manage global and domestic adverse events for drug, biologic, vaccine, device, and combination products, with built-in gateway connections and reporting rules to streamline submissions to health authorities. According to Veeva’s product page, the application was announced in 2019, is in mature status, and serves 51 to 100 customers.
Company Context
Veeva delivers an industry cloud for life sciences with applications, agents, data, and consulting, serving more than 1,500 customers ranging from the largest pharmaceutical companies to emerging biotechs. The company operates as a Public Benefit Corporation, which Veeva says commits it to balancing the interests of customers, employees, shareholders, and the industries it serves.
Falcon Safety’s early adopter availability is planned for November 2026, the same window Veeva has set for its first clinical, regulatory, and safety agents.
